Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lineage switch in acute leukemia.

S Stass, J Mirro, S Melvin

    Blood
    |September 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood.

    Leukemia & lymphoma·2016
    Same author

    A revised definition for cure of childhood acute lymphoblastic leukemia.

    Leukemia·2014
    Same author

    Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

    Cancer chemotherapy and pharmacology·2014
    Same author

    Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL).

    Pediatric blood & cancer·2014
    Same author

    Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.

    Journal of the National Cancer Institute·2012
    Same journal

    Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

    Blood·2026
    Same journal

    Identifying steroid-refractory aGVHD before it happens.

    Blood·2026
    Same journal

    ELISA-negative HIT: antibody recognition and relevance.

    Blood·2026
    Same journal

    EBV and immunodeficiency: the odd couple drawn to the brain.

    Blood·2026
    Same journal

    A bone to pick with ferric carboxymaltose.

    Blood·2026
    Same journal

    A step toward streamlining HIT diagnosis.

    Blood·2026
    See all related articles

    Lineage switch, the conversion between lymphoid and myeloid leukemia, occurred in 6.7% of childhood leukemia relapses. Prompt recognition and appropriate retreatment are crucial for managing these unexpected conversions.

    Area of Science:

    • Hematology
    • Oncology
    • Pediatric Medicine

    Background:

    • Leukemia cell lineage conversion (lymphoid to myeloid or vice versa) is a rare phenomenon.
    • Understanding the mechanisms and frequency of lineage switch is critical for effective leukemia treatment.

    Purpose of the Study:

    • To investigate the frequency and characteristics of leukemic cell lineage switch in pediatric patients experiencing bone marrow relapse.
    • To evaluate the impact of lineage switch on treatment response and outcomes.

    Main Methods:

    • Retrospective review of 89 childhood leukemia cases with bone marrow relapse.
    • Analysis of cytochemical and immunophenotypic features to identify lineage switch.
    • Correlation of lineage switch with treatment history, response, and cytogenetic findings.

    Related Experiment Videos

    Main Results:

    • Six out of 89 patients (6.7%) exhibited lineage switch.
    • Five patients converted from acute lymphoblastic leukemia (ALL) to acute nonlymphoblastic leukemia (ANLL), and one from ANLL to ALL.
    • Four patients achieved second remissions after treatment tailored to the switched phenotype; two failed ALL-directed therapy.

    Conclusions:

    • Lineage switch occurs with unexpected frequency in pediatric leukemia relapses after intensive chemotherapy.
    • Prompt identification of lineage switch and appropriate retreatment strategies are essential for improving patient outcomes.
    • Potential mechanisms include chemotherapy-induced eradication of the dominant clone allowing expansion of a secondary clone or drug-induced alterations in differentiation programs.